First Trust Advisors
CCCC icon

First Trust Advisors’s C4 Therapeutics CCCC Stock Holding History

First Trust Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-86,952
Closed -$3.88M – 2521
2021
Q3 		$3.88M Buy
86,952
+64,688
+291% +$2.77M ﹤0.01% 1471
2021
Q2 		$842K Buy
+22,264
New +$797K ﹤0.01% 2102

Other funds holding CCCC

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

First Trust Advisors's CCCC Position: Q4 2021 in Review

First Trust Advisors sold out of C4 Therapeutics (CCCC) in Q4 2021, closing a stake of 86,952 shares — an estimated $3.88M sold.

First Trust Advisors first reported a position in CCCC in Q2 2021 and held it in 2 quarters. The position peaked at $3.88M in Q3 2021. 119 funds tracked by Wall St. Rank hold CCCC as of Q4 2021.

  • First Trust Advisors reported no remaining C4 Therapeutics position as of Q4 2021 after selling out during the quarter.
  • First Trust Advisors sold 86,952 C4 Therapeutics shares in Q4 2021, an estimated $3.88M.
  • First Trust Advisors first reported a position in C4 Therapeutics in Q2 2021 and held it in 2 quarters.
  • First Trust Advisors's C4 Therapeutics position peaked at $3.88M in Q3 2021.
  • 119 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2021.

Based on First Trust Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.